

# Respiratory Syncytial Virus Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/R09BDA7FAF06EN.html>

Date: May 2024

Pages: 134

Price: US\$ 6,499.00 (Single User License)

ID: R09BDA7FAF06EN

## Abstracts

The 7 major respiratory syncytial virus markets reached a value of US\$ 1.3 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 3.8 Billion by 2034, exhibiting a growth rate (CAGR) of 10.01% during 2024-2034.

The respiratory syncytial virus market has been comprehensively analyzed in IMARC's new report titled "Respiratory Syncytial Virus Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Respiratory syncytial virus refers to a common medical condition that causes infections of the lungs and respiratory tract. The disease is highly contagious and can spread via respiratory droplets when an infected individual sneezes or coughs. It can also be transmitted through direct contact with contaminated surfaces. This ailment can result in a range of symptoms, from mild cold-like indications, such as runny nose, coughing, fever, etc., to more serious problems, including bronchiolitis and pneumonia. Individuals suffering from the disorder may also experience discomfort and difficulty swallowing, rapid or labored breathing, wheezing, fatigue, decreased energy levels, bluish coloration of the skin, lips, or nail beds, weakness, lack of appetite, etc. The diagnosis of respiratory syncytial virus typically requires a combination of the patient's characteristic findings, a physical examination, and a medical history evaluation. A rapid antigen test, which involves collecting a nasal or throat swab and then analyzing it for the presence of viral antigens, is also utilized for the diagnosis. The healthcare provider may further perform reverse transcription polymerase chain reaction (RT-PCR) techniques to detect the genetic material of the virus in the respiratory secretions.

The increasing cases of airborne transmission of pathogens through nasal droplets when an infected individual coughs or sneezes, are primarily driving the respiratory

syncytial virus market. In addition to this, the rising prevalence of weakened immune systems due to premature birth, advancing age, chronic lung or heart diseases, etc., is also creating a positive outlook for the market. Moreover, the widespread adoption of specialized respiratory interventions, such as chest physiotherapy and airway clearance techniques, which help to loosen mucus and improve breathing in individuals suffering from the ailment, is further bolstering the market growth. Apart from this, the inflating application of effective drugs, like bronchodilators, antipyretics, antivirals, etc., to reduce symptoms and enhance the quality of life in patients is acting as another significant growth-inducing factor. Additionally, the emerging popularity of therapeutic vaccines, since they stimulate the immune system to recognize and mount a more robust response against the pathogen, thereby providing long-term disease protection, is expected to drive the respiratory syncytial virus market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the respiratory syncytial virus market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for respiratory syncytial virus and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the respiratory syncytial virus market in any manner.

### Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

### Countries Covered

United States

Germany

France

United Kingdom  
Italy  
Spain  
Japan

### Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario

Historical, current, and future performance of the respiratory syncytial virus market

Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the respiratory syncytial virus market

Reimbursement scenario in the market

In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current respiratory syncytial virus marketed drugs and late-stage pipeline drugs.

### In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

### Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

\*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

How has the respiratory syncytial virus market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the respiratory syncytial virus market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the respiratory syncytial virus market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

### Epidemiology Insights

What is the number of prevalent cases (2018-2034) of respiratory syncytial virus across the seven major markets?

What is the number of prevalent cases (2018-2034) of respiratory syncytial virus by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of respiratory syncytial virus by gender across the seven major markets?

How many patients are diagnosed (2018-2034) with respiratory syncytial virus across the seven major markets?

What is the size of the respiratory syncytial virus patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of respiratory syncytial virus?

What will be the growth rate of patients across the seven major markets?

### Respiratory Syncytial Virus: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for respiratory syncytial virus drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the respiratory syncytial virus market?

What are the key regulatory events related to the respiratory syncytial virus market?

What is the structure of clinical trial landscape by status related to the respiratory syncytial virus market?

What is the structure of clinical trial landscape by phase related to the respiratory syncytial virus market?

What is the structure of clinical trial landscape by route of administration related to the respiratory syncytial virus market?

## Contents

### **1 PREFACE**

### **2 SCOPE AND METHODOLOGY**

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
  - 2.3.1 Primary Sources
  - 2.3.2 Secondary Sources
- 2.4 Market Estimation
  - 2.4.1 Bottom-Up Approach
  - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

### **3 EXECUTIVE SUMMARY**

### **4 RESPIRATORY SYNCYTIAL VIRUS - INTRODUCTION**

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

### **5 RESPIRATORY SYNCYTIAL VIRUS - DISEASE OVERVIEW**

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

### **6 PATIENT JOURNEY**

### **7 RESPIRATORY SYNCYTIAL VIRUS - EPIDEMIOLOGY AND PATIENT POPULATION**

- 7.1 Epidemiology - Key Insights
- 7.2 Epidemiology Scenario - Top 7 Markets
  - 7.2.1 Epidemiology Scenario (2018-2023)
  - 7.2.2 Epidemiology Forecast (2024-2034)
  - 7.2.3 Epidemiology by Age (2018-2034)
  - 7.2.4 Epidemiology by Gender (2018-2034)
  - 7.2.5 Diagnosed Cases (2018-2034)
  - 7.2.6 Patient Pool/Treated Cases (2018-2034)
- 7.3 Epidemiology Scenario - United States
  - 7.3.1 Epidemiology Scenario (2018-2023)
  - 7.3.2 Epidemiology Forecast (2024-2034)
  - 7.3.3 Epidemiology by Age (2018-2034)
  - 7.3.4 Epidemiology by Gender (2018-2034)
  - 7.3.5 Diagnosed Cases (2018-2034)
  - 7.3.6 Patient Pool/Treated Cases (2018-2034)
- 7.4 Epidemiology Scenario - Germany
  - 7.4.1 Epidemiology Scenario (2018-2023)
  - 7.4.2 Epidemiology Forecast (2024-2034)
  - 7.4.3 Epidemiology by Age (2018-2034)
  - 7.4.4 Epidemiology by Gender (2018-2034)
  - 7.4.5 Diagnosed Cases (2018-2034)
  - 7.4.6 Patient Pool/Treated Cases (2018-2034)
- 7.5 Epidemiology Scenario - France
  - 7.5.1 Epidemiology Scenario (2018-2023)
  - 7.5.2 Epidemiology Forecast (2024-2034)
  - 7.5.3 Epidemiology by Age (2018-2034)
  - 7.5.4 Epidemiology by Gender (2018-2034)
  - 7.5.5 Diagnosed Cases (2018-2034)
  - 7.5.6 Patient Pool/Treated Cases (2018-2034)
- 7.6 Epidemiology Scenario - United Kingdom
  - 7.6.1 Epidemiology Scenario (2018-2023)
  - 7.6.2 Epidemiology Forecast (2024-2034)
  - 7.6.3 Epidemiology by Age (2018-2034)
  - 7.6.4 Epidemiology by Gender (2018-2034)
  - 7.6.5 Diagnosed Cases (2018-2034)
  - 7.6.6 Patient Pool/Treated Cases (2018-2034)
- 7.7 Epidemiology Scenario - Italy
  - 7.7.1 Epidemiology Scenario (2018-2023)
  - 7.7.2 Epidemiology Forecast (2024-2034)

- 7.7.3 Epidemiology by Age (2018-2034)
- 7.7.4 Epidemiology by Gender (2018-2034)
- 7.7.5 Diagnosed Cases (2018-2034)
- 7.7.6 Patient Pool/Treated Cases (2018-2034)
- 7.8 Epidemiology Scenario - Spain
  - 7.8.1 Epidemiology Scenario (2018-2023)
  - 7.8.2 Epidemiology Forecast (2024-2034)
  - 7.8.3 Epidemiology by Age (2018-2034)
  - 7.8.4 Epidemiology by Gender (2018-2034)
  - 7.8.5 Diagnosed Cases (2018-2034)
  - 7.8.6 Patient Pool/Treated Cases (2018-2034)
- 7.9 Epidemiology Scenario - Japan
  - 7.9.1 Epidemiology Scenario (2018-2023)
  - 7.9.2 Epidemiology Forecast (2024-2034)
  - 7.9.3 Epidemiology by Age (2018-2034)
  - 7.9.4 Epidemiology by Gender (2018-2034)
  - 7.9.5 Diagnosed Cases (2018-2034)
  - 7.9.6 Patient Pool/Treated Cases (2018-2034)

## **8 RESPIRATORY SYNCYTIAL VIRUS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES**

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

## **9 RESPIRATORY SYNCYTIAL VIRUS - UNMET NEEDS**

## **10 RESPIRATORY SYNCYTIAL VIRUS - KEY ENDPOINTS OF TREATMENT**

## **11 RESPIRATORY SYNCYTIAL VIRUS - MARKETED PRODUCTS**

- 11.1 List of Respiratory Syncytial Virus Marketed Drugs Across the Top 7 Markets
  - 11.1.1 Synagis (Palivizumab) - AstraZeneca
    - 11.1.1.1 Drug Overview
    - 11.1.1.2 Mechanism of Action
    - 11.1.1.3 Regulatory Status
    - 11.1.1.4 Clinical Trial Results
    - 11.1.1.5 Sales Across Major Markets
  - 11.1.2 Abrysvo (Respiratory Syncytial Virus Vaccine) - Pfizer



- 11.1.2.1 Drug Overview
- 11.1.2.2 Mechanism of Action
- 11.1.2.3 Regulatory Status
- 11.1.2.4 Clinical Trial Results
- 11.1.2.5 Sales Across Major Markets
- 11.1.3 Arexvy (Respiratory syncytial virus vaccine adjuvanted) - GlaxoSmithKline
  - 11.1.3.1 Drug Overview
  - 11.1.3.2 Mechanism of Action
  - 11.1.3.3 Regulatory Status
  - 11.1.3.4 Clinical Trial Results
  - 11.1.3.5 Sales Across Major Markets
- 11.1.4 Nirsevimab - Sanofi
  - 11.1.4.1 Drug Overview
  - 11.1.4.2 Mechanism of Action
  - 11.1.4.3 Regulatory Status
  - 11.1.4.4 Clinical Trial Results
  - 11.1.4.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report

## **12 RESPIRATORY SYNCYTIAL VIRUS - PIPELINE DRUGS**

- 12.1 List of Respiratory Syncytial Virus Pipeline Drugs Across the Top 7 Markets
  - 12.1.1 RSVPreF - Hvivo
    - 12.1.1.1 Drug Overview
    - 12.1.1.2 Mechanism of Action
    - 12.1.1.3 Clinical Trial Results
    - 12.1.1.4 Safety and Efficacy
    - 12.1.1.5 Regulatory Status
  - 12.1.2 EDP-938 - Enanta Pharmaceuticals
    - 12.1.2.1 Drug Overview
    - 12.1.2.2 Mechanism of Action
    - 12.1.2.3 Clinical Trial Results
    - 12.1.2.4 Safety and Efficacy
    - 12.1.2.5 Regulatory Status
  - 12.1.3 MV-012-968 - Meissa Vaccines
    - 12.1.3.1 Drug Overview
    - 12.1.3.2 Mechanism of Action
    - 12.1.3.3 Clinical Trial Results

- 12.1.3.4 Safety and Efficacy
- 12.1.3.5 Regulatory Status
- 12.1.4 BLB-201 - Blue Lake Biotechnology
  - 12.1.4.1 Drug Overview
  - 12.1.4.2 Mechanism of Action
  - 12.1.4.3 Clinical Trial Results
  - 12.1.4.4 Safety and Efficacy
  - 12.1.4.5 Regulatory Status
- 12.1.5 mRNA-1345 - ModernaTX
  - 12.1.5.1 Drug Overview
  - 12.1.5.2 Mechanism of Action
  - 12.1.5.3 Clinical Trial Results
  - 12.1.5.4 Safety and Efficacy
  - 12.1.5.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report

### **13. RESPIRATORY SYNCYTIAL VIRUS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS**

### **14. RESPIRATORY SYNCYTIAL VIRUS – CLINICAL TRIAL LANDSCAPE**

- 14.1 Drugs by Status
- 14.2 Drugs by Phase
- 14.3 Drugs by Route of Administration
- 14.4 Key Regulatory Events

### **15 RESPIRATORY SYNCYTIAL VIRUS - MARKET SCENARIO**

- 15.1 Market Scenario - Key Insights
- 15.2 Market Scenario - Top 7 Markets
  - 15.2.1 Respiratory Syncytial Virus - Market Size
    - 15.2.1.1 Market Size (2018-2023)
    - 15.2.1.2 Market Forecast (2024-2034)
  - 15.2.2 Respiratory Syncytial Virus - Market Size by Therapies
    - 15.2.2.1 Market Size by Therapies (2018-2023)
    - 15.2.2.2 Market Forecast by Therapies (2024-2034)
- 15.3 Market Scenario - United States
  - 15.3.1 Respiratory Syncytial Virus - Market Size

- 15.3.1.1 Market Size (2018-2023)
- 15.3.1.2 Market Forecast (2024-2034)
- 15.3.2 Respiratory Syncytial Virus - Market Size by Therapies
  - 15.3.2.1 Market Size by Therapies (2018-2023)
  - 15.3.2.2 Market Forecast by Therapies (2024-2034)
- 15.3.3 Respiratory Syncytial Virus - Access and Reimbursement Overview
- 15.4 Market Scenario - Germany
  - 15.4.1 Respiratory Syncytial Virus - Market Size
    - 15.4.1.1 Market Size (2018-2023)
    - 15.4.1.2 Market Forecast (2024-2034)
  - 15.4.2 Respiratory Syncytial Virus - Market Size by Therapies
    - 15.4.2.1 Market Size by Therapies (2018-2023)
    - 15.4.2.2 Market Forecast by Therapies (2024-2034)
  - 15.4.3 Respiratory Syncytial Virus - Access and Reimbursement Overview
- 15.5 Market Scenario - France
  - 15.5.1 Respiratory Syncytial Virus - Market Size
    - 15.5.1.1 Market Size (2018-2023)
    - 15.5.1.2 Market Forecast (2024-2034)
  - 15.5.2 Respiratory Syncytial Virus - Market Size by Therapies
    - 15.5.2.1 Market Size by Therapies (2018-2023)
    - 15.5.2.2 Market Forecast by Therapies (2024-2034)
  - 15.5.3 Respiratory Syncytial Virus - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
  - 15.6.1 Respiratory Syncytial Virus - Market Size
    - 15.6.1.1 Market Size (2018-2023)
    - 15.6.1.2 Market Forecast (2024-2034)
  - 15.6.2 Respiratory Syncytial Virus - Market Size by Therapies
    - 15.6.2.1 Market Size by Therapies (2018-2023)
    - 15.6.2.2 Market Forecast by Therapies (2024-2034)
  - 15.6.3 Respiratory Syncytial Virus - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
  - 15.7.1 Respiratory Syncytial Virus - Market Size
    - 15.7.1.1 Market Size (2018-2023)
    - 15.7.1.2 Market Forecast (2024-2034)
  - 15.7.2 Respiratory Syncytial Virus - Market Size by Therapies
    - 15.7.2.1 Market Size by Therapies (2018-2023)
    - 15.7.2.2 Market Forecast by Therapies (2024-2034)
  - 15.7.3 Respiratory Syncytial Virus - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain

- 15.8.1 Respiratory Syncytial Virus - Market Size
  - 15.8.1.1 Market Size (2018-2023)
  - 15.8.1.2 Market Forecast (2024-2034)
- 15.8.2 Respiratory Syncytial Virus - Market Size by Therapies
  - 15.8.2.1 Market Size by Therapies (2018-2023)
  - 15.8.2.2 Market Forecast by Therapies (2024-2034)
- 15.8.3 Respiratory Syncytial Virus - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
  - 15.9.1 Respiratory Syncytial Virus - Market Size
    - 15.9.1.1 Market Size (2018-2023)
    - 15.9.1.2 Market Forecast (2024-2034)
  - 15.9.2 Respiratory Syncytial Virus - Market Size by Therapies
    - 15.9.2.1 Market Size by Therapies (2018-2023)
    - 15.9.2.2 Market Forecast by Therapies (2024-2034)
  - 15.9.3 Respiratory Syncytial Virus - Access and Reimbursement Overview

## **16 RESPIRATORY SYNCYTIAL VIRUS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS**

## **17 RESPIRATORY SYNCYTIAL VIRUS MARKET - SWOT ANALYSIS**

- 17.1 Strengths
- 17.2 Weaknesses
- 17.3 Opportunities
- 17.4 Threats

## **18 RESPIRATORY SYNCYTIAL VIRUS MARKET – STRATEGIC RECOMMENDATIONS**

## **19 APPENDIX**

## I would like to order

Product name: Respiratory Syncytial Virus Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/R09BDA7FAF06EN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/R09BDA7FAF06EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

